MAPT and Alzheimer disease: These polymorphs may influence the disease’s progressionand severity.37,38 Dual Inhibitors of amyloid-βand tau aggregation with amyloid-β disaggregating propertieswere recently suggested as new multifunctional ligands that wouldaffect different stages of AD pathogenesis.31 Tauvid has been approved by the US FDA for PET imaging tau pathologyin AD.39